
Neuropharmacology, Год журнала: 2024, Номер unknown, С. 110282 - 110282
Опубликована: Дек. 1, 2024
Язык: Английский
Neuropharmacology, Год журнала: 2024, Номер unknown, С. 110282 - 110282
Опубликована: Дек. 1, 2024
Язык: Английский
Medicina Clínica, Год журнала: 2025, Номер unknown
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
3Neuropeptides, Год журнала: 2025, Номер 110, С. 102503 - 102503
Опубликована: Янв. 9, 2025
Язык: Английский
Процитировано
1Nature Reviews Endocrinology, Год журнала: 2025, Номер unknown
Опубликована: Фев. 11, 2025
Язык: Английский
Процитировано
1Medicina Clínica (English Edition), Год журнала: 2025, Номер 164(6), С. 295 - 304
Опубликована: Март 1, 2025
Язык: Английский
Процитировано
0Pharmacology & Therapeutics, Год журнала: 2025, Номер unknown, С. 108846 - 108846
Опубликована: Апрель 1, 2025
Class B G protein-coupled receptors (GPCRs) are a subfamily of 15 peptide hormone with diverse roles in physiological functions and disease pathogenesis. Over the past decade, several novel therapeutics targeting these have been approved for conditions like migraine, diabetes, obesity, many which ground-breaking first-in-class. Most agonist analogues modified endogenous sequences to enhance receptor activation or stability. Several small molecule monoclonal antibody antagonists also late-stage development. Differences sequence structure therapeutic ligands lead distinct signalling profiles, including biased behaviour inhibition specific pathways. Understanding this pharmacology offers unique development opportunities improving efficacy reducing adverse effects. This review summarises current knowledge on ligand bias class GPCR drugs, highlights strategies refine exploit their pharmacological discusses key considerations related structure, localisation, regulation developing new therapies.
Язык: Английский
Процитировано
0Hans Journal of Medicinal Chemistry, Год журнала: 2025, Номер 13(02), С. 194 - 209
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
0Frontiers in Pharmacology, Год журнала: 2025, Номер 16
Опубликована: Май 30, 2025
Anxiety and depression represent two of the most prevalent mental disorders worldwide, with current pharmacotherapies often limited by adverse effects treatment resistance. Consequently, research into natural products for health interventions has attracted growing scientific interest. Quercetin, a bioactive flavonoid ubiquitously present in plant-derived flowers, fruits, dietary sources, exhibits diverse pharmacological properties, including antioxidant, anxiolytic, antidepressant activities. This review systematically summarizes fundamental characteristics quercetin, focusing on its core molecular mechanisms alleviating anxiety- depression-like behaviors, preclinical evidence from experimental models, landscape clinical investigations. By critically analyzing therapeutic advantages, translational challenges, emerging priorities, this synthesis aims to offer theoretical foundation development quercetin-based formulations their implementation mood disorder management.
Язык: Английский
Процитировано
0European Journal of Pharmacology, Год журнала: 2025, Номер unknown, С. 177809 - 177809
Опубликована: Июнь 1, 2025
Язык: Английский
Процитировано
0Journal of Integrative Neuroscience, Год журнала: 2024, Номер 23(12)
Опубликована: Дек. 24, 2024
The coexistence of anxiety or depression with coronary heart disease (CHD) is a significant clinical challenge in cardiovascular medicine. Recent studies have indicated that hypothalamic-pituitary-adrenal (HPA) axis activity could be promising focus understanding and addressing the development treatments for comorbid CHD depression. HPA helps to regulate levels inflammatory factors, thereby reducing oxidative stress damage, promoting platelet activation, stabilizing gut microbiota, which enhance survival regeneration neurons, endothelial cells, other cell types, leading neuroprotective cardioprotective benefits. This review addresses relevance nervous systems, as well latest research advancements regarding its mechanisms action. discussion includes detailed function regulating processes mentioned. Above all, it summarizes therapeutic potential biomarker atherosclerotic combined
Язык: Английский
Процитировано
2Frontiers in Endocrinology, Год журнала: 2024, Номер 15
Опубликована: Сен. 27, 2024
Phoenixin (PNX) is an emerging neuropeptide that plays a significant role in regulating metabolism and reproduction. This comprehensive review examines findings from human, vivo , vitro studies to elucidate the functions of PNX metabolic processes. has been identified as key player essential pathways, including energy homeostasis, glucose, lipid electrolyte metabolism, mitochondrial dynamics. It modulates food fluid intake, influences glucose profiles, affects biogenesis function. abundantly expressed hypothalamus, where it crucial reproductive hormone secretion maintaining balance. Furthermore, also peripheral tissues such heart, spleen, pancreas, indicating its involvement regulation across central systems. therapeutic peptide operates through G protein-coupled receptor 173 (GPR173) at molecular level. activates signaling pathways cAMP-protein kinase A (PKA) Epac-ERK, which are for regulation. Research suggests may be effective managing disorders like obesity type 2 diabetes, well health issues infertility. Since processes closely linked reproduction, further understanding PNX’s these areas necessary develop management/treatments. aims highlight identify gaps current knowledge regarding impact on human health. Understanding mechanisms action development novel strategies treatment issues, public concerns globally.
Язык: Английский
Процитировано
1